Active Ingredient History

NOW
  • Now
Surotomycin was an investigational oral antibiotic. This antibiotic was under investigation by Merck & Co for the treatment of life-threatening Diarrhea, commonly caused by the bacterium Clostridium difficile. After reaching phase III in clinical trials, its production was discontinued in 2017 due to its non-superiority to current therapies.   Wikipedia

  • SMILES: CCCCCc1ccc(cc1)\C(=C\C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](CC(=O)c5ccccc5N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC4=O)[C@H](C)CC(=O)O)\C
  • InChIKey: DYNMYYRPPFVAKR-ZXTAUSOFSA-N
  • Mol. Mass: 1680.75
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry
cb-183,315 | surotomycin

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue